/ /


Extensive analysis confirms treat-and-extend regimens reliable for AMDIn patients with age-related macular degeneration managed by a treat-and-extend regimen, the visual acuity generally was maintained; lesion reactivation occurred frequently at about eight weeks; and longer induction phases between treatments was associated with worse outcomes.
Vitrectomy offers a viable therapeutic option for DMEMaurice B. Landers III, MD, presents an argument that in an era when pharmacological therapy has become the mainstay for the treatment of diabetic macular edema (DME), pars plana vitrectomy (PPV) deserves consideration as a reasonable alternative for early DME in appropriate patients.
No strategies exist to lower glaucoma risk; healthy habits offer starting pointAlthough there are no scientifically proven ways to prevent glaucoma, healthy habits–such as moderate exercise, regular visual check-ups, and eating green, leafy vegetables–represent a good starting point for a prevention strategy.
Investigating strains on ONH tissue key to unraveling mystery of glaucomaInvestigations of the biomechanical changes in the optic nerve head may eventually lead to improvements in therapies for patients with glaucoma.
Are you aware of the available resources for AMD?Since February is designated Age-Related Macular Degeneration Awareness month. For healthcare providers, there are numerous resources available to help promote awareness to patients and to encourage patients to continue (or start) annual visual exams.
Systematic review brings awareness to treat-and-extend for AMDA well-known dilemma surrounding AMD is that there lacks a universally accepted treatment regimen with anti-VEGF injections. The balance between optimal visual outcomes and treatment burden has led some specialists to embrace the treat-and-extend regimen over monthly treatments.
Put to the testI have an idea. The idea is based upon what seems to be an almost-universally accepted belief that before there should be widespread use of surgical or medical therapies to treat patients with diseases, those therapies should first be vetted in controlled clinical trials involving a limited sample of the afflicted population.
Novel glaucoma drugs close at handA review of glaucoma drugs in various clinical study phases reveals that at least seven new glaucoma drugs were in trials and two others were approved by the FDA in 2017. Many drugs that have progressed the most act on prostaglandin receptors, though some combine this with other mechanisms of action.
Identifying glaucoma-related visual function lossA portable device for detecting multifocal steady-state visual evoked potentials associated with visual field stimulation is being developed as an objective test for identifying glaucoma-related visual function loss.
Neuropathic dry eye: When serum defeats tearsOphthalmology Times is pleased to announce Melina I. Morkin, MD, and Pedram Hamrah, MD, FACS, of New England Eye Center/Tufts Medical Center, Department of Ophthalmology, Tufts University School of Medicine, Boston, as the third-place winner of the 2017 Resident Writer’s Award Program, sponsored by Allergan. Their entry is featured here.